TheraRadar
← Back
Data updated: Jun 28, 2026

PLIVA HRVATSKA DOO

Generics

PLIVA HRVATSKA DOO is a generic drug manufacturer focused on Cardiovascular, Neurology.

2006
Since
8
Drugs
-
Trials
0
New Drugs (2yr)

PLIVA HRVATSKA DOO's Key Drugs

PLIVA HRVATSKA DOO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PLIVA HRVATSKA DOO's Recent FDA Approvals

New NDA/BLA approvals for PLIVA HRVATSKA DOO over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PLIVA HRVATSKA DOO's Therapeutic Areas

PLIVA HRVATSKA DOO's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 67%
2 drugs
Neurology 33%
1 drugs

PLIVA HRVATSKA DOO's Top Competitors

PLIVA HRVATSKA DOO's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PLIVA HRVATSKA DOO Pipeline Snapshot

Active clinical trials for PLIVA HRVATSKA DOO across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling